Changlong Hou
Overview
Explore the profile of Changlong Hou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
57
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang S, Song R, Hou C, Yao H, Xu J, Zhou H, et al.
J Hepatocell Carcinoma
. 2025 Feb;
12:219-229.
PMID: 39931181
Purpose: Liver venous deprivation (LVD; simultaneous portal vein embolization and hepatic vein embolization) has been the latest surgical strategy for rapid future liver remnant (FLR) hypertrophy. The aim of this...
2.
Qin J, Yuan X, Zheng H, Qi C, Guo Y, Zhu Z, et al.
Transplantation
. 2024 Sep;
109(3):387-390.
PMID: 39344006
No abstract available.
3.
Hou C, Xiong B, Zhou L, Fei Y, Shi C, Zhu X, et al.
BMC Cancer
. 2024 Mar;
24(1):387.
PMID: 38539150
Background: The safety and efficacy of transarterial chemoembolization plus molecular targeted therapy (MTT) combined with immune checkpoint inhibitors (ICIs) in primary liver cancer have been demonstrated. However, the evidence for...
4.
Liu K, Zheng X, Dai J, Hou C, Lu D, Zhao B, et al.
Acad Radiol
. 2024 Mar;
31(10):4034-4044.
PMID: 38508935
Rationale And Objectives: Transarterial chemoembolization (TACE) plus molecular targeted therapies has emerged as the main approach for treating hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT). A robust model...
5.
Liu K, Zheng X, Lu D, Tan Y, Hou C, Dai J, et al.
Radiol Med
. 2023 Oct;
129(1):14-28.
PMID: 37863847
Objective: Exploring the efficacy of a Radiological-Clinical (Rad-Clinical) model in predicting prognosis of unresectable hepatocellular carcinoma (HCC) patients after drug eluting beads transcatheter arterial chemoembolization (DEB-TACE) to optimize the targeted...
6.
Xiong B, Fu B, Wu Y, Gao F, Hou C
J Cancer Res Clin Oncol
. 2023 Jul;
149(13):11607-11617.
PMID: 37400572
Purpose: Immune checkpoint inhibitors (ICIs) with anti-PD-1/PD-L1 antibody are promising treatments for hepatocellular carcinoma (HCC), but lack reliable biomarkers of response. In the present study, we aimed to investigate the...
7.
Xia H, Hou C, Liu T, Bao H, Fan K, Chen Q, et al.
Minerva Med
. 2023 Feb;
114(3):402-404.
PMID: 36756866
No abstract available.
8.
Chen W, Hong L, Hou C, Zong G, Zhang J
Am J Transl Res
. 2022 Jun;
14(5):2988-3002.
PMID: 35702084
Background: LncRNA LINC00665 partakes in controlling the malignant phenotype of cancer cells, but its role in glioma and the related regulatory mechanism remain uncertain. Methods: RT-PCR was exploited to examine...
9.
Chen W, Hou C, Wang Y, Hong L, Wang F, Zhang J
Neurosci Lett
. 2022 Apr;
782:136638.
PMID: 35447224
Background: Parkinson's disease (PD) is a neurodegenerative disorder that is featured by the elevated loss of substantia nigra pars compacta dopaminergic neurons and the disruption of motor functions. Aberrant expression...
10.
Zhu X, Shi C, Hou C
Nutr Cancer
. 2022 Apr;
74(9):3363-3374.
PMID: 35404727
Objective: Gallbladder carcinoma (GBC) is a common malignancy of the biliary tract that, with late diagnosis, is often fatal. A better understanding of the underlying molecular mechanisms may facilitate targeted...